A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Trial status:Recruiting
Trial ID:
BNT324-01
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial Details
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Medical Condition
Trial Drug
See more
Phase
Phase 1/Phase 2
Type
Interventional
Estimated Enrolment
594
Estimated Trial Date
May 2025 - Aug 2027
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Precision NextGen Oncology and Research Center
Beverly Hills, California, United States, 90212
Status
Recruiting
Location
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, United States, 07601
Status
Recruiting
Location
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Status
Recruiting
Location
Hacettepe University Medical Faculty
Ankara, Unmapped, 06100
Status
Recruiting
Location
Bristol Haematology and Oncology Centre
Bristol, United Kingdom, BS2 8ED
Status
Recruiting
Location
University College London Hospital
London, United Kingdom, W1T 7HA
Status
Recruiting